Current Report Filing (8-k)
September 20 2017 - 2:40PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 20, 2017
PhaseRx, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37772
|
20-4690620
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
410 W. Harrison Street, Suite 300
Seattle, Washington
|
98119
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(206) 805-6300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
x
On September 20, 2017, the PhaseRx, Inc.
(the “Company”) issued a press release announcing that the Company received orphan drug designation from the U.S. Food
and Drug Administration for its second drug candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency. A copy
of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits
.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PhaseRx, Inc.
|
|
|
|
Date: September 20, 2017
|
By:
|
/s/ Robert W. Overell
|
|
|
Robert W. Overell, Ph.D.
|
|
|
Chief Executive Officer
|
PhaseRx (CE) (USOTC:PZRXQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
PhaseRx (CE) (USOTC:PZRXQ)
Historical Stock Chart
From Apr 2023 to Apr 2024